article thumbnail

Heart failure services from the community perspective in the UK: a cross-sectional survey

The British Journal of Cardiology

Heart failure (HF) is a highly prevalent long-term condition, with variation in services and resources across the UK. This report provides findings from a cross-sectional survey of community HF services in the UK between September 2021 and February 2022. Eighty-five responses describing community HF services were received.

article thumbnail

Heart failure services from the hospital perspective in the UK: a cross-sectional survey

The British Journal of Cardiology

Heart failure (HF) is a significant problem in the UK with variation in services across the country. Here we describe the findings from a cross-sectional survey of HF services in the UK performed between September 2021 and February 2022. The clinical lead in 82% of hospitals was a cardiologist with specialist interest in HF.

article thumbnail

Cardiovascular outcomes in long COVID-19: a systematic review and meta-analysis

Frontiers in Cardiovascular Medicine

Systematic search conducted without language restrictions from December 1, 2019 to June 31, 2022 on PubMed, EMBASE, Web of Science, Cochrane library, ProQuest Coronavirus Research Database, COVID-19 Living Overview of the Evidence (L-OVE) subset of Episteminokos and the World Health Organization (WHO) Covid-19 databases.

article thumbnail

New Study Published in JACC: Heart Failure Reveals that Despite Significant Efforts to Improve Acute Heart Failure Treatment Over the Past 20 Years, Management Remains Unchanged

DAIC

(‘Reprieve’), a development stage company focused on pioneering an intelligent approach to acute decompensated heart failure (ADHF) treatment, today highlighted the publication of TREAT-AHF study results in JACC: Heart Failure. Heart failure (HF) is a leading cause of hospitalization in the United States.

article thumbnail

AskBio Receives FDA Fast Track Designation for AB-1002 Investigational Gene Therapy Program in Congestive Heart Failure

DAIC

Inhibiting the function of this protein, which is linked to congestive heart failure (CHF), could potentially lead to a therapeutic effect on the heart.1,2 Inhibiting the function of this protein, which is linked to congestive heart failure (CHF), could potentially lead to a therapeutic effect on the heart.1,2

article thumbnail

Dual-task training and cognitive performance in individuals with coronary artery disease and/or heart failure: a systematic review

Frontiers in Cardiovascular Medicine

The aim of this study is to describe the literature on the relationship between motor-cognitive DTT and cognitive performance (CP) in individuals with coronary artery disease (CAD) and/or heart failure (HF).MethodThis Searches were performed in the MEDLINE/Pubmed, Scielo, Lilacs, PEDro, and EMBASE databases.

article thumbnail

AskBio Announces Initiation of Phase 2 GenePHIT Trial in Congestive Heart Failure (CHF)

DAIC

(AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG , announced that it is initiating GenePHIT (Gene PHosphatase Inhibition Therapy), a Phase 2 trial of AB-1002 (also known as NAN-101 ) for the treatment of congestive heart failure (CHF). Heart failure. Published 2022.